Marker Therapeutics Inc (MRKR)

[microcapbiotech]

WOW, now that's kind of weird. I just figured,
#1 If Gilead who already owned a bunch was willing to put in another 11 million at $3.75, I don't think Gilead is stupid and would just throw good money after bad (if they thought it was bad).
#2 I wanted to buy it at 20% less than Gilead did.
#3 They did a Phase 2 proof-of-concept trial for HTC where 95% of patients who received posoleucel demonstrated a predefined clinical response and 88% of patients remaining free of clinically significant infections caused by any of the six viruses that posoleucel targets through the Week 14 primary endpoint.
I believe they started their Phase 3 HTC trial and are currently recruiting at 89 locations around the world.
Also did a Phase 2 proof-of-concept trial in kidney transplant recipients.
#4 Already got the posoleucel designations (Orphan etc. etc.) from the FDA and EMA.
#5 Also working on ALVR106 and ALVR107.
#6 If I understand correctly, similar to MRKR, more than half the shares are held by insiders and institutions (40% insiders and 35% institutions), so 25% "available" float to trade which would be about 28 million shares "available".
#7, NOT similar to MRKR, ALVR has over 7 million shares shorted, which is like 2 to 4 weeks worth of "days to cover", or 25% of the 28 million "available", so if any good news, big short squeeze = Much Higher Price.
#8 As crazy as it sounds, I like the Ann Leen factor/connection?
Please feel free to fact check my assumptions, especially #'s 6 and 7.
Good Luck Phantom, Good Luck Patients.
GO MRKR, GO ALVR, GO Juan Vera and GO Ann Leen